March 28 (Reuters) - The U.S. Food and Drug
Administration approved French drugmaker Sanofi's
therapy, paving the way for a new type of treatment for patients
12 years of age and older with a rare disorder that prevents
blood from clotting properly, the regulator said on Friday.